At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
Researchers are assessing the safety of the drug VT3989 in people with mesothelioma. The people in this study have mesothelioma with a mutation (change or variant) in the NF2 gene.
-
Researchers in this study want to find the best dose of STAR0602 to use in people with advanced solid tumors. The people in this study have cancer that is inoperable (cannot be taken out with surgery) or metastatic (has spread). STAR0602 boosts the immune system to stop tumor growth. It is given intravenously (by vein).
-
Researchers want to see how well the drug enasidenib works in people with angioimmunoblastic T-cell lymphoma (AITL). The people in this study have AITL that came back or keeps growing after treatment. Their cancers also have a mutation (change) in the IDH2 gene.
-
PF-07799544 and PF-07799933 both work by blocking proteins that promote melanoma growth. PF-07799544 blocks a family of proteins called MEK and PF-07799933 inhibits the BRAF protein. Both drugs are taken orally (by mouth).
-
Researchers are doing this study to see if Revaree Plus improves vaginal health in people treated for breast cancer. The people in this study are having symptoms of vaginal dryness or discomfort during breast cancer treatment.
-
Researchers are measuring the safety of ivonescimab when given with standard lung cancer treatments and seeing how well it works. The people in this study have been newly diagnosed with squamous non-small cell lung cancer that has metastasized (spread).
- A Phase 1/2 Study of Afamitresgene Autoleucel SPEAR T Cell Therapy in Children and Young Adults With Solid Tumors
Full Title A Phase 1/2, Open-Label, Basket Study to Assess the Safety, Tolerability, and Anti-Tumor Activity of Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors
Purpose
Researchers are assessing a new type of therapy in young people with solid tumors that keep growing even after treatment. The therapy is called afamitresgene autoleucel. The people in this study have synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST), neuroblastoma, or osteosarcoma. In addition, they have tested positive for the HLA-A*02 gene and their cancers make a protein called MAGE-A4. This protein plays a role in cancer growth.
Afamitresgene autoleucel is a cellular therapy made from your white blood cells called T cells. Some cancers block T cells from attacking cancer cells. If you join this study, we will first collect some of your T cells and add a small piece of DNA. This will help your T cells find and kill cancer cells that make MAGE-A4. These genetically changed T cells are called “specific peptide enhanced affinity receptor” (SPEAR) T cells. Treatments made from them are called SPEAR T cell therapies.
When it nears the time for you to get afamitresgene autoleucel, you will first get fludarabine and cyclophosphamide. These two chemotherapy drugs prepare your body to receive the cellular therapy. Afamitresgene autoleucel is then given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You or your child must:
- Have synovial sarcoma, MPNST, neuroblastoma, or osteosarcoma that keeps growing even with treatment.
- Have the HLA-A*02 gene and a cancer that makes MAGE-A4.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 2-21 years.
Contact
For more information and to see if you or your child can join this study, please call 1-833-MSK-KIDS.
Protocol
23-244Phase
Phase I/II (phases 1 and 2 combined)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT05642455ClinicalTrials.gov
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
The purpose of this study is to assess the safety and effectiveness of partial breast radiation therapy given over a three-day period (three weekdays in a row) in women with ductal carcinoma in situ (DCIS) or early-stage invasive breast cancer after lumpectomy. Women who are not in a research study usually receive radiation therapy to the whole breast over three weeks or receive partial breast irradiation over a five- to ten-day period.
-
Unfavorable intermediate-risk prostate cancers have not spread beyond the prostate but have a chance of coming back. They are usually treated with surgery or radiation therapy, with or without hormonal therapy. One of the more common standard treatment approaches is hormonal therapy called androgen deprivation therapy (ADT), which reduces the levels of male sex hormones, followed by external beam radiation therapy (EBRT) to the prostate and nearby lymph nodes.